From January 1, 2024 to March 31, 2024, the company has repurchased 11,804,907 shares, representing 1.45% for CNY 222.56 million. With this, the company has completed the repurchase of 17,763,061 shares, representing 2.2% for CNY 345.45 million under the buyback announced on July 17, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
29.33 CNY | +2.41% | +6.50% | +31.94% |
26/04 | Jafron Biomedical Co.,Ltd. Proposes Final Dividend for the Year 2023 | CI |
25/04 | Jafron Biomedical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+31.94% | 3.07B | |
-4.91% | 183B | |
+0.46% | 108B | |
-3.62% | 67.51B | |
+3.26% | 50.67B | |
+9.11% | 44.7B | |
+2.41% | 40.95B | |
+6.39% | 26.8B | |
+3.83% | 26.71B | |
+12.66% | 24.62B |
- Stock Market
- Equities
- 300529 Stock
- News Jafron Biomedical Co.,Ltd.
- Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on July 17, 2023.